Systems and methods for biomolecule detection
By combining cells with samples, interacting with biomolecules, and using microfluidic channels to detect changes in cell properties, the problems of insufficient sensitivity and high cost of biomolecule detection in the prior art are solved, and efficient and accurate multi-dimensional biomolecular detection.
Patent Information
- Application Number
- CN202380033777.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-10
- Filing Date
- 2023-02-27
- Publication Date
- 2024-11-22
AI Technical Summary
The existing biomolecular detection methods have problems such as insufficient sensitivity, high cost and long detection time, especially when detecting the presence of different types of biomolecules in samples.
By binding the cells to the sample, the biomolecules to be detected interact with the cells, thereby changing the properties of the cells and detecting these changes using microfluidic channels to infer the presence, deletion and concentration of the biomolecules. The method involves using subpopulations of cells from different sources, encoding fluorescent molecules and receptors, to detect multiple biological molecules simultaneously.
It achieves high diagnostic accuracy and in-depth understanding of the pathogenesis of the disease, and can detect multiple biological molecules simultaneously, improving the specificity, sensitivity and efficiency of the detection, and reducing sample processing volume.
Smart Images

Figure CN119013559A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to systems and methods for detecting biomolecules in a sample. Background Art
[0002] In the fields of biology, biotechnology, medicine and diagnostic procedures, characterizing samples by detecting biomolecules is an important starting point for many applications. This includes monitoring the presence or absence of biomolecules in samples and their changes for biochemical research, medical diagnosis, predicting treatment response, understanding disease pathogenesis and drug development. For example, when new pathogens emerge, analyzing samples from infected individuals by detecting biomolecules can help diagnose related diseases, prevent or suppress outbreaks, monitor the course of disease progression or post-disease symptoms, and develop appropriate treatment measures.
[0003] The limitations of existing methods for biomolecular detection have become prominent during the coronavirus disease-19 (COVID-19) pandemic, an ongoing global pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which affects the pulmonary system and impairs microcirculation (acute phase). Four weeks or more after the first infection with SARS-CoV-2 (see, e.g., Post-COVID Conditions | CDC; NICE, www.nice.org.uk / guidance / ng188), some patients develop persistent post-COVID-19 health problems (long COVID-19, also known as Post-Acute Sequelae of SARS-CoV-2 infection, PASC), such as respiratory sequelae, neurological and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal diseases, malaise, fatigue, musculoskeletal pain, and anemia (as described by Al-Aly et al., doi: 10.1038 / s41586-021-03553-9). The underlying mechanism may be driven by abnormal immune responses, hyperactivation of the immune system, or autoimmunity. Specifically, patients infected with SARS-CoV-2 have higher levels of autoantibodies than uninfected individuals. Autoantibodies damage the patient's immune system (e.g., by attacking B cells, depleting interferons (IFNs)) or attack the patient's own tissues (e.g., by targeting proteins in the patient's blood vessels, connective tissues, and brain).
[0004] In addition, other diseases are characterized by the immune system attacking the patient's own tissues (autoimmunity), including type 1 diabetes (T1D), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), Graves' disease, Hashimoto's thyroiditis, Alzheimer's disease, Huntington's disease, inflammatory bowel disease (IBD), Crohn's disease, and coeliac disease. disease) (e.g., as described in [6] Burbelo and O'Hanlon, doi: 10.1097 / BOR.0000000000000107; [8] Morgenthaler et al., doi: 10.1055 / s-2007-978858). Another relevant publication in this regard is Wallukat et al., Anti-β1-Adrenoceptor Autoantibodies with Chronotropic Activity from the Serum of Patients with Dilated Cardiomyopathy: Mapping of Epitopes in the First and Second Extracellular Loops, J. Mol. Cell Cardiol. 27, 397-406.
[0005] Specific antibody-antigen interactions can be used to detect the presence of biomolecules in a sample (such as autoantibodies in a blood sample). In an enzyme-linked immunosorbent assay (ELISA), binding to a target protein or peptide is studied. Despite its widespread use, ELISA has several limitations, including insufficient sensitivity levels (e.g., due to the use of a single antibody) and low signal to background noise levels (e.g., due to cross-reactions when two antibodies are used, or nonspecific binding of antibodies to plastic surfaces).
[0006] Higher sensitivity can be achieved in complex multi-step screening strategies where ELISA is combined with immunofluorescence and other assays. For example, to detect β1-adrenergic receptor autoantibodies in patients with cardiomyopathy, a disease of the heart muscle, ELISA is combined with immunofluorescence in cells expressing native human β-adrenergic receptor (β-AR) and cyclic adenosine monophosphate (cAMP), which can be detected by exchange protein activated by cAMP (Epac) fluorescence resonance energy transfer (FRET) detection (Nikolaev et al., doi: 10.1016 / j.jacc.2007.03.051) or by an assay that determines protein kinase A (PKA) activity (SignaTECT PKA assay) (Yu, Stavrakis et al., doi: 10.1016 / j.jash.2011.10.003). Although these complex multi-step screening strategies offer improved sensitivity over ELISA, they are limited to specific applications and do not allow for the simultaneous detection of the presence of different types of biomolecules in a sample.
[0007] Existing methods for biomolecule detection are currently subject to various limitations, including low sensitivity, high cost and long procedure duration (as described in [1] Drucker and Krapfenbauer, doi:10.1186 / 1878-5085-4-7; [2], Mayeux, doi:10.1602 / neurorx.1.2.182; [3], Nimse et al., doi:10.1039 / c5an01790d).
[0008] Therefore, there is a need in the art for a new system and method for detecting the presence, absence or concentration of biomolecules (such as autoantibodies) in a sample. In addition, there is a need for a new system and method for effectively detecting biomolecules in real time to appropriately diagnose and treat diseases or post-disease symptoms. Summary of the invention
[0009] The present invention meets or solves at least some of the above needs and aims to solve the above problems in the art by providing systems and methods as defined by the independent claims.Preferred embodiments are set out in the respective dependent claims and in the embodiments described below.
[0010] The present invention includes a method for detecting one or more biomolecules in a sample. The method includes the steps of: (i) combining the sample with cells (e.g., by adding the cells to the sample), (ii) detecting at least one property of the cells that changes in response to the biomolecule, and (iii) inferring the presence, absence, and / or concentration of the biomolecule. The change is determined relative to a control group (e.g., a reference value for the property of the cell).
[0011] One aspect of the invention is the detection of biomolecules associated with a particular condition in a sample obtained from a patient (e.g., suspected disease, post-disease symptoms, recovery from disease, immunization via vaccination, treatment, etc.). To detect the presence of the biomolecule, cells are configured such that the biomolecule to be detected can interact with the cell, thereby altering one or more properties of the cell. The interaction of the biomolecule with the cell can be characterized by binding of the biomolecule to a receptor involved in the pathogenesis of the disease. The present systems and methods enable clinical phenotypes of patients, provide high diagnostic accuracy, and can provide insight into disease pathogenesis or appropriate treatment options.
[0012] One aspect of the present invention is to detect autoantibodies in patient body fluids (e.g., blood, saliva, urine, or cerebrospinal fluid). The autoantibodies produced under physiological or pathophysiological conditions can be used as indicators of disease-promoting conditions, diseases (e.g., autoimmune diseases) or symptoms after diseases (e.g., long-term neurological and / or heart disease symptoms). When a sample with autoantibodies is added to a cell (e.g., mammalian cell) expressing a receptor (e.g., cell surface molecule, such as a protein with an extracellular region) for autoantibodies, the autoantibodies interact with the receptors, and thereby change one or more properties of the cell. By comparing the detected properties with a reference value, the presence or absence of autoantibodies can be inferred. The present system and method detect autoantibodies with high specificity, sensitivity, repeatability, and sample handling capacity in the sample.
[0013] One aspect of the present invention is to detect a change in at least one property of a cell in the presence or absence of a biomolecule by using a microfluidic channel. The microfluidic channel can be part of a microfluidic device (e.g., a chip) by which samples and cells can be analyzed in less than 0.001 seconds by continuously phenotyping the cells in a non-contact manner.
[0014] One aspect of the present invention includes a method for simultaneously detecting at least two different types of biomolecules (e.g., antibodies) in a sample. This includes adding a sample including at least two different biomolecules to a cell population (cell population) (e.g., mammalian cells) including at least two cell subpopulations or cells having different sources. Cell subpopulations / cell groups having different sources can be genetically modified for detecting biomolecules, wherein the cells include: (i) heterologous nucleic acids encoding fluorescent molecules for identifying cells, wherein, in the presence of biomolecules, the behavior of the fluorescent molecules is not affected; and (ii) natural or heterologous nucleic acids encoding receptors for specific binding to biomolecules, wherein, in the presence of biomolecules, the receptors change at least one property of cells that can be detected (e.g., cell mass density, cell size, or mechanical properties). In the cell population, at least two modified cells differ in features (i) and (ii). These two features can be detected simultaneously, for example, by simultaneous mechanical characterization and fluorescence characterization. Cells of different sources can only bind to one specific biomolecule and initially have different sizes or are labeled with different fluorescent markers.
[0015] Therefore, the present invention provides systems and methods for biomolecule detection by providing preferred embodiments described below:
[0016] 1. A method for detecting biomolecules in a sample, the method comprising:
[0017] - adding cells to the sample, the cells being arranged so that the biomolecule to be detected can interact with the cells, thereby changing one or more properties of the cells,
[0018] - detect the properties of cells, and
[0019] - Comparing the detected property with a reference value to infer the presence or absence of the biomolecule and / or the concentration of the biomolecule.
[0020] 2. A method according to embodiment 1, wherein the detection of the properties of the cells is performed in a microfluidic channel, wherein the sample is guided through the microfluidic channel, wherein preferably the detected properties include mechanical properties, and wherein the cells preferably deform within the channel.
[0021] 3. The method according to embodiment 1 or 2, wherein the cell is configured so that the interaction of the biomolecule with the cell is the binding of the biomolecule with a receptor of the cell.
[0022] 4. A method according to any of the preceding embodiments, wherein the cell is configured so that more than one type of biomolecule can interact with the cell, and wherein different types of biomolecules result in different detectable changes in a property of the cell.
[0023] 5. A method according to any of the preceding embodiments, wherein the properties include one or more of the cell's size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties (such as Raman and / or Brillouin scattering), dielectric and acoustic impedance and / or deformability, elasticity and viscosity.
[0024] 6. The method according to any one of the preceding embodiments, wherein the cell is a mammalian cell, and
[0025] Optionally, the cells include or consist of natural cells, transfected cells and / or synthetic cells.
[0026] 7. A method according to any of the preceding embodiments, wherein the cell is configured to change its properties when exposed to a biomolecule, and wherein the biomolecule is an antibody that interacts with a receptor of the cell, preferably a cell surface molecule, optionally wherein the antibody is an autoantibody targeting G protein coupled receptors (GPCRs).
[0027] 8. The method according to any of the preceding embodiments, further comprising using the detected property to infer the concentration of the biomolecule in the sample.
[0028] 9. The method according to any one of the preceding embodiments, wherein the sample is a fluid, preferably a liquid;
[0029] Optionally, wherein the fluid is obtained from a subject, further optionally, wherein the fluid is saliva, blood, excreta and / or a body fluid, preferably, wherein the excreta is urine, and / or wherein the body fluid is cerebrospinal fluid (CSF); and
[0030] Optionally, wherein the subject is a mammal.
[0031] 10. A method for detecting at least two types of biomolecules in a sample, the method comprising:
[0032] - adding a cell population to the sample; wherein the cell population comprises at least two cell subpopulations or at least two cell groups from different sources:
[0033] The first cell subpopulation / group is arranged such that a first type of biomolecule to be detected can interact with cells of the first cell subpopulation / group, and the first cell subpopulation / group is characterized by a fluorescent behavior,
[0034] and the second cell subpopulation / group is arranged so that a second type of biomolecule to be detected can interact with cells of the second cell subpopulation / group, and the second cell subpopulation / group is characterized by a different fluorescence behavior compared to the first cell subpopulation / group; and
[0035] wherein the cell is configured so that the biomolecule to be detected can interact with the cell, thereby changing one or more properties of the cell;
[0036] - Detect cell properties and cell fluorescence behavior;
[0037] - Compare the detected property with a reference value to infer the presence or absence of the biomolecule;
[0038] - comparing the fluorescence behavior of the cells to assign the detected change in the property to a first type of cell or a second type of cell; and
[0039] - inferring the presence or absence of a first type of biomolecule, and the presence or absence of a second type of biomolecule.
[0040] 11. A method according to embodiment 10, wherein the types of biomolecules are different biomolecules that interact with cells, optionally wherein the biomolecules bind to different receptors of the cells.
[0041] 12. The method according to embodiment 10 or 11, wherein the biomolecules are antibodies and the types of biomolecules are antigenically distinct antibodies,
[0042] Among them, the first type of antibodies can interact with cells of the first cell subpopulation / group but cannot interact with cells of the second cell subpopulation / group, and the second type of antibodies can interact with cells of the second cell subpopulation / group but cannot interact with cells of the first cell subpopulation / group.
[0043] 13. A method according to any one of embodiments 10 to 12, wherein the detected property of the cells is mechanical properties, and wherein the mechanical properties and fluorescence behavior of the cells are detected in a microfluidic channel.
[0044] 14. A kit configured for detecting a biomolecule, the kit comprising:
[0045] - one or more cells arranged so that the biomolecule to be detected can interact with the cells and thereby change one or more properties of the cells,
[0046] - a device for detecting one or more properties of a cell, the kit preferably being arranged for use in a method according to one of the preceding claims.
[0047] 15. A kit for use in a method of detecting one or more biomolecules in a sample obtained from a subject, preferably wherein the sample is saliva, blood, urine or cerebrospinal fluid (CSF). BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 is a set of schematic diagrams showing the detection of biomolecules using antibodies as an example. When a biomolecule interacts with a receptor of a cell (eg, a cell surface molecule), changes in one or more properties of the cell can be detected.
[0049] Figure 2 A system is described in which cells expressing surface molecules pass through a microfluidic channel in the presence or absence of a biomolecule to be detected.
[0050] Figure 3 The detection of at least two different types of biomolecules in a sample by a cell population including at least two cell subpopulations is exemplified. In order to detect, for example, two different biomolecules A and B in a sample, two cell subpopulations A and B can be used. Cell subpopulation A expresses (i) a receptor A specific for biomolecule A and (ii) a fluorescent molecule A specific for cell A. Cell subpopulation B expresses (i) a receptor B specific for biomolecule B and (ii) a fluorescent molecule B specific for cell B. When the changes in the physical properties of the cells (e.g., cell mass density, cell size, or mechanical properties) read are combined with the fluorescent signals of cell subpopulations A and B, it can be inferred that biomolecules A and / or B are present in the cell pool.
[0051] Figure 4 The present disclosure is illustrated by the use of real-time deformability cytometry (RT-DC) for characterizing cellular mechanics of human cells when incubated with a biomolecule. The biomolecule is an agonist for a G-protein coupled receptor (GPCR), i.e., the β2 adrenergic receptor. Specifically, HL60 human myeloid leukemia cells were incubated with drugs that activate GPCRs or patient-derived serum containing autoantibodies targeting GPCRs (including the β2 adrenergic receptor). Deformability cytometry plots are shown in (a), (b), and (c), representing the deformation for each cellular event and its corresponding measured cell area (μm 2 ). Figure 4(a): Control group measurement results of HL60 cells without addition of biomolecules (reference value). Figure 4 (b): Measurement results of HL60 cells incubated with drugs (β2 agonists). Figure 4 (c): Measurement results of HL60 cells incubated with patient sera containing β2 autoantibodies. Figure 4 (d): Contourplots of all measurements in (a), (b) and (c). The right image shows two representative images of cells with (treated) and without (untreated) added β2 GPCR specific molecules. DETAILED DESCRIPTION
[0052] definition
[0053] All publications, patents, and patent applications cited herein are incorporated by reference in their entirety for all purposes.
[0054] According to the present invention, each occurrence of the term "comprising" may optionally be replaced by the term "consisting of". Unless clearly indicated by contrast, the articles "a / an" and "the" used herein refer to one or more than one (e.g., at least one) of the grammatical objects of the article. For example, "element" means one element or more than one element. Unless the context clearly indicates otherwise, the term "or" used herein means the term "and / or" and can be used interchangeably with the term "and / or".
[0055] As used herein, the term "about" refers to a deviation of ±10% from the stated value. When the word "about" is used herein to refer to a number, it is understood that yet another embodiment includes the number not modified by the presence of the word "about". In the absence of the term "about", and unless the context indicates otherwise, generally accepted rounding rules apply to the specified value.
[0056] As used herein, the term "biomolecule" refers to a substance present in a living cell or organism (e.g., intracellular and extracellular) under physiological or disease conditions or after treatment. Biomolecules can be nucleic acids (including oligonucleotides of nucleotides such as deoxyribonucleotides or ribonucleotides), polypeptides and proteins (such as antibodies / autoantibodies), carbohydrates and lipids. In one aspect, biomolecules can be derived from samples of healthy subjects to analyze physiological functions associated with natural organ function, homeostasis, aging or regeneration. The function can also be analyzed based on changes in the environment. In other cases, after injury, biomolecules can be derived from the target area to analyze temporary or permanent changes during injury, fibrosis or scar formation. In other cases, biomolecules can also be derived from vaccinated individuals and compared with samples of unvaccinated or infected individuals. In other cases, biomolecules can also be derived from pathological conditions, such as organ dysplasia, autoimmune diseases, chronic diseases, infectious diseases or cancers, and compared with samples of healthy or cured individuals. In addition, the biomolecule can be a clinical marker for a disease or disorder (e.g., an abnormal immune biomarker, a clinical severity marker), a predictive marker for a disease (e.g., a marker of thromboinflammatory activation), or a therapeutic biomarker. The biomolecule can be a ligand (agonist or antagonist) specific for a natural or synthetic receptor of a cell.
[0057] As used herein, the term "at least two types of biomolecules" refers to biomolecules that interact differently with a cell, for example by binding to different receptors of the cell. Different interactions of the types of biomolecules can result in detectable changes in the same or different properties of the cell when compared to a reference value (e.g., morphology and rheological parameters are quantified for the two types of biomolecules, such as cell size, elasticity, or deformability). In some cases, the at least two types of biomolecules are characterized in that they have different structures. In some cases, the at least two types of biomolecules can be antibodies that differ in antigenicity, for example, differ in the amino acid sequence of one or more CDRs of each of the variable domains of the light and heavy chains, the target antigen, the functional characteristics, and / or a set of specific amino acids of the antigen that are specifically recognized and bound by the antibody (epitope).
[0058] As used herein, the term "sample" refers to a composition comprising at least one biomolecule of interest. The sample may be processed prior to analysis. For example, the sample may be processed (e.g., lyophilized or frozen) for transport and / or storage. The sample may be a diagnostic sample for identifying a group of patients characterized by, for example, an infection or disease. The sample may include one, two or more biomolecules of interest, such as nucleic acids, proteins, carbohydrates, lipids, and combinations thereof.
[0059] As used herein, the term "fluid" refers to a solution, for example, a liquid sample. The feature of a fluid is its composition, for example, including at least one or more biomolecules, its chemical composition (for example, ion concentration), osmotic concentration (osmotic concentration, osmolarity) (the number of solute particles in every 1L solvent, temperature dependence), pH and its ability to affect cells suspended in a fluid (for example, considering the tension of the ability of a fluid to pass through a cell membrane; osmotic pressure, etc.). Fluid can be a body fluid such as saliva, blood (for example, serum, plasma, cerebrospinal fluid) and / or excreta (for example, urine, feces) obtained from a subject, for detecting a target biomolecule. Patient-derived body fluid can be used for diagnosis or treatment of a disease. In addition, it can be used for detecting or monitoring a disease (for example, autoimmune disease, infectious disease), assessing the risk and / or efficiency of treatment, prevention or gene screening. Body fluid can include hormones, steroids, antibodies, growth factors, cytokines and chemokines, nucleic acids, proteins and / or drugs.
[0060] As used herein, the term "cell" refers to a single cell of any cell type. Specifically, the cell is characterized in that it can change one or more properties of the cell when interacting with the target biomolecule (such as, for characterizing the morphology and rheological parameters of the cell biomechanical characteristics). The cell can be a eukaryotic cell, preferably a mammalian cell, more preferably a human, mouse, rat or hamster cell. The cell can be derived from a multicellular organism or a part thereof (for example, an animal tissue). The cell can be characterized by its age, developmental stage and physiology or disease state. Cells for detecting biomolecules can naturally express surface molecules ("natural cells") that specifically interact with the biomolecules, for example, endothelial cells, hemogenic neutrophils and monocytes, smooth muscle cells, hepatogenic hepatocytes, renal nephrocytes and podocytes. Alternatively, cells can be genetically modified to express natural or heterologous receptors that interact with the target biomolecule ("modified cells"). For microfluidic-based methods, cells preferably have smooth profiles.
[0061] As used herein, the term "transfected cell" refers to a cell in which a nucleic acid (DNA or RNA), protein, or ribonucleoprotein (RNP) complex is intentionally introduced to modify the cell. Transfection can utilize standard techniques known to the skilled artisan. Transfection can be stable or transient (over a limited period of time). For stable transfection, the exogenous nucleic acid can be integrated into the genome of the cell.
[0062] As used herein, the term "synthetic cell" refers to a modified cell of non-natural origin. Synthetic cells are engineered particles that mimic one or more functions of biological cells. The design and construction of synthetic cells include surface molecules and specific biochemical mechanisms that explain the interaction of biological molecules with surface molecules through one or more changes in the physical parameters of the synthetic cell.
[0063] As used herein, the term "cell population" refers to a mixture of at least two cell subpopulations. Compared with other subpopulations in the cell population, each cell subpopulation is characterized by a unique fluorescence behavior (that is, it can be distinguished from the fluorescence behavior of other subpopulations) and a unique interaction with a target biomolecule (that is, a specific type of biomolecule can only interact with a cell subpopulation, but not with other cell subpopulations). When there is or is absent a target biomolecule, the fluorescence behavior of each cell subpopulation remains unchanged (that is, the parameter is constant between the sample and the reference value). Therefore, determining that the fluorescence behavior allows the identity of the cell subpopulation to be maintained when determining cell properties. The unique interaction with the target biomolecule is read by monitoring the change of the properties (such as mechanical properties) of the cell when the biomolecule exists (that is, the property changes between the sample and the reference value).
[0064] As used herein, the term "subject" refers to a multicellular organism such as a mammal. The subject can be an experimental animal, such as a bat, a rodent (e.g., a mouse, a rat, a guinea pig, a hamster, etc.), a non-human primate (e.g., a macaque, a marmoset, a tamarin, a monkey, a baboon, etc.), or a human. The subject can be characterized by its age, developmental stage, and physiological or disease state. For example, the subject can be a patient suspected of having a disease, post-disease symptoms, recovering from a disease, being immunized by vaccination, being treated, etc.
[0065] As used herein, the term "cell property" refers to a structural and / or functional characteristic of a cell. Structural characteristics may include one or more of cell size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties (such as Raman and / or Brillouin scattering), dielectric and acoustic impedance, and / or deformability and viscosity.
[0066] As used herein, the term "mechanical properties of cells" refers to mechanical phenotypes of cells that can be measured, for example, by traditional methods (e.g., atomic force microscopy, micropipette aspiration, optical stretching, parallel plate rheology) or microfluidics-based methods. Microfluidics-based methods can include constriction-based deformability cytometry (cDC), shear flow deformability cytometry (sDC) such as real-time deformability cytometry (RT-DC), real-time 1D-imaging fluorescence and deformability cytometry (RT-FDC), real-time analysis of physical phenotype in deformational flow (RAPID) and extensional flow deformability cytometry (xDC) (e.g., described in [5], Urbanska et al., doi: 10.1038 / s41592-020-0818-8). Measurements of cell mechanics can avoid the need for exogenous labeling (e.g., fluorescent dyes). For example, RT-DC is a label-free, high-throughput technique that allows for rapid image-based mechanistic interrogation of cells at a rate of hundreds of cells per second (see Otto et al., doi: 10.1038 / nmeth.3281).
[0067] As used herein, the term "elasticity" or "stiffness" refers to a biophysical marker or mechanical phenotype of a cell. Cell elasticity refers to the ability of a cell to deform in response to external stress.
[0068] As used herein, the term "deformability" refers to the ability of a cell to change its shape. Deformability is a biophysical marker or mechanical phenotype of a cell and can be quantified by the parameter cell deformation d, for example, measured by deformability cytometry (DC). To this end, cells can be illuminated with pulsed high-power LEDs (short enough to prevent motion blur of the cells) and imaged at 2,000-4,000 fps with a complementary metal-oxide semiconductor (CMOS) camera. In contraction-based DC (cDC) cells, cell deformability is defined as the inverse of the cell's transit time. In extended flow DC (xDC), cells are stretched by extended flows typically associated with cross-groove microfluidic architectures, and cell deformability is defined as the maximum aspect ratio observed in the extended flow region. In shear flow DC (sDC) such as RT-DC, cells are driven into a funnel-shaped constriction in a microfluidic channel, where they deform into a bullet-like shape under shear forces and pressure gradients, and cell deformation is defined as "1-circular" (see, e.g. Figure 1 [5], Urbanska et al., doi:10.1038 / s41592-020-0818-8).
[0069] As used herein, the term "transit time" refers to a characteristic property of cells measured by microfluidics-based methods. For example, in the specific cDC setting mentioned by Urbanska et al., the transit time of untreated HL60 cells is 23 ms, requiring a processing throughput of several cells per second (e.g., [5], Urbanska et al., doi:10.1038 / s41592-020-0818-8).
[0070] As used herein, the term "physical phenotype" refers to a biophysical marker of a cell, including its state and function. Such biophysical markers can be valuable in clinical diagnosis. The physical phenotype of a cell has been widely used to understand biological processes occurring during the development or disease of an organism. Methods for evaluating and analyzing different aspects of a physical phenotype are known to those skilled in the art (e.g., [4], Wu et al., doi: 10.1038 / s41592-018-0015-1; [5], Urbanska et al., doi: 10.1038 / s41592-020-0818-8).
[0071] As used herein, the term "concentration" refers to the ratio between the amount of solute and the amount of solution, and describes how many moles are present per unit volume of the final solution (mol / L).
[0072] As used herein, the term "absence" refers to an amount or concentration of a biomolecule below a detection limit that can be detected by a method selected to detect a property that changes in the presence of the biomolecule. Methods for assessing detection limits are known to those skilled in the art.
[0073] As used herein, the term "receptor" refers to a specific interaction or binding site of a biomolecule that changes one or more properties of a cell when interacting, such as by controlling, regulating or adjusting a cellular process. For example, the binding of a biomolecule (ligand) to a receptor (e.g., a cell surface molecule) can result in a conformational change (e.g., by changing its tertiary structure), which can trigger a sequential event leading to a biological response, such as activating downstream effectors, leading to activation or inhibition of a specific cellular process (e.g., a signaling pathway). A receptor can be a cell surface molecule, such as a protein with an extracellular region that acts as a receptor for a specific biomolecule. An example of a cell surface receptor is a G protein coupled receptor (GPCRs), which detects extracellular biomolecules (agonists) and activates a cell response.
[0074] As used herein, the term "interaction" refers to the attractive molecular forces between biomolecules and cells, such as by binding. The interaction can be direct or indirect, and results in changes in one or more properties of cells (e.g., such as the size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties, dielectric and acoustic impedance and / or deformability and viscosity) that can be detected (e.g., in the case of cells passing through a microfluidic channel). Interactions between ligands and receptors, antibodies and antigens, biomolecules and receptors can be observed, for example, plasma membrane-associated molecules, such as sugar residues of proteins, glycoproteins or glycolipids, carbohydrate receptors on cell surfaces. The interaction of biomolecules (in liquid samples) with cells can depend on chemical components (e.g., ion concentration), osmotic concentration (number of solute particles per 1L solvent, temperature dependence) and osmotic weight (osmotic concentration, osmolality) (number of solute particles in 1kg solvent, independent of temperature), pH, temperature, pressure, flow rate, conductivity, voltage and / or current.
[0075] As used herein, the term "binding" refers to the interaction of a biomolecule with a cell. When a biomolecule is close to a living cell, an interaction can occur between the molecule and the cell. One form of interaction, but not limited to, is the specific binding of a biomolecule (such as an antibody) to a molecule (receptor) expressed on the surface of the cell. The interaction of a biomolecule with a living cell can be accompanied by changes in one or more physical properties of the cell. Binding can be based on electrostatic interactions of only a few residues (e.g., amino acids or sugar residues) and can be sensitive to structural polymorphisms or mutations present in the biomolecule. The binding of biomolecules can result in reversible or irreversible changes in cellular properties.
[0076] As used herein, the term "reference value" refers to a value or a set of values used to interpret the value of a test sample (e.g., for properties of cells such as size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties, dielectric and acoustic impedance, and / or deformability and viscosity). For example, if a test sample is present or not in the presence of a specific biomolecule, the reference value refers to the value of at least one property measured for the cell under the same conditions (e.g., experimental conditions and setup) in the absence of the specific biomolecule.
[0077] As used herein, the term "change" refers to any form of physical or chemical change. For example, this can include activation or inhibition of a receptor, the effect of a mutation on a receptor (e.g., for detecting mutant cells with specific physiological characteristics), the effect of receptor and / or biomolecule concentrations.
[0078] As used herein, the term "detectable change" refers to a difference in the measurable properties of a cell due to the interaction of a biomolecule with a cell. For example, the binding of an agonist (biomolecule, such as an autoantibody) to a G protein-coupled receptor (GPCR) results in a conformational change in the GPCR and downstream signal transduction, which can be detected by, for example, RT-DC analysis, for example, as described by Urbanska et al., doi: 10.1016 / bs.mcb.2018.06.009. This detectable change is strong enough to be observed externally by studying a single cell or a population of cells.
[0079] As used herein, the term "detection method" refers to an analysis system for cell physical phenotypes. Detection can be performed by frequency shift and / or imaging combined with real-time or subsequent analysis of the detected phenotype. Phenotypic analysis can be performed in less than 0.001 seconds. For microfluidic-based methods, a chip including a microfluidic channel and a CMOS camera can be used. The chip can be characterized by a specific chip geometry, such as a square channel cross section (e.g., in sDC), a rectangular cross section (e.g., in xDC). The production of exemplary chips (e.g., polydimethylsiloxane, PDMS chips) is described in, for example, Otto et al. (doi:10.1038 / nmeth.3281) or Herbig et al. (doi:10.1007 / 978-1-4939-7346-0_15), including silicon wafer master preparation and chip production. Other methods for detection are analytical equipment known to those skilled in the art.
[0080] As used herein, the term "microfluidic channel" refers to conveying, mixing, separating or otherwise processing fluids geometrically limited to a small scale, where surface forces dominate volume forces. In a microfluidic system, fluids can be precisely controlled and manipulated by active components (e.g., micropumps or microvalves). The size of the square cross-section of a microfluidic channel (e.g., a closed channel) can be between about 100 nm and about 500 μm.
[0081] As used herein, the term "fluorescent behavior" refers to a fluorescent signal that can be detected by methods known to those skilled in the art. Fluorescence analysis can include background determination and / or other comparative measurements. In some cases, fluorescent behavior refers to cells that include heterologous nucleic acids encoding fluorescent molecules (e.g., fluorescent chemical compounds, fluorophores, or fluorochromes).
[0082] As used herein, the term "antibody" refers to a ligand that recognizes, binds or interacts with an antigen.
[0083] As used herein, the term "autoantibody" refers to an antibody that recognizes, binds to, or interacts with an antigen typically found in a subject, a subject's tissue, or a cell. Autoantibodies are examples of target biomolecules. For example, autoimmune diseases or disorders are characterized by the production of autoantibodies that attack healthy cells. Autoantibodies can be produced in patients several years before the disease or disorder is detected, and can be used as an early predictor of risk and possible therapeutic intervention.
[0084] As used herein, the term "G protein-coupled receptor" or "GPCR" refers to a receptor located on the cell surface that can mediate the transmission of intracellular signals by activating a guanine nucleotide binding protein (G protein) coupled to the receptor. The binding of a specific ligand (e.g., a biomolecule) to a GPCR can cause a conformational change in the receptor, resulting in a form that can bind and activate the G protein, thereby initiating a series of events that can lead to a biological response.
[0085] Implementation
[0086] The details of the invention are set forth in the description below.
[0087] Detecting biomolecules in samples through mechanical characterization
[0088] One aspect of the invention includes detecting biomolecules in a sample by mechanical characterization, wherein the cells are arranged so that the biomolecules to be detected can interact with the cells, thereby changing one or more mechanical properties of the cells. These properties include cell size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties (such as Raman and / or Brillouin scattering), dielectric and acoustic impedance, elasticity and / or deformability and / or viscosity. In some cases, the interaction of the biomolecules with the cells changes the fluorescence behavior of the cells. In some cases, the cells are arranged so that more than one type of biomolecule can interact with the cells (e.g., simultaneously), and different types of biomolecules result in different detectable changes in cell properties.
[0089] The step of detecting the cell properties can be carried out in a microfluidic channel, wherein the liquid test sample is guided through the microfluidic channel. The advantage of the method based on microfluidics is its amazing high processing capacity. This includes being able to process many cells in a very short time (e.g., at a speed of up to 1000 cells per second), and simultaneously detecting several properties of the cell (e.g., morphology and rheological parameters). In some cases, several properties of the cell, such as physical parameters, can be detected or quantified simultaneously.
[0090] In some cases, cell properties are measured by microfluidic-based techniques that rely, for example, on measuring the transit time of cells through microcontractions or on estimating cell deformations caused by fluid dynamics. If target biomolecules are present in the sample, they interact with the cells by specifically binding to the receptors of the target biomolecules, resulting in detectable changes in the mechanical properties of the cells. Preferably, real-time deformability cytometry (RT-DC) is applied to detect changes in the mechanical properties of cells at high measurement speeds in real time. RT-DC uses a microfluidic chip to restrict the flow of suspended cells. The cells are driven into a funnel-shaped constriction in a microfluidic channel and then guided into a straight channel, where they are deformed into a bullet shape under the action of shear forces and pressure gradients, as described in WO2015 / 024690A1 or Urbanska et al., doi:10.1016 / bs.mcb.2018.06.009. Figure 1 At the end of the channel, the mechanical properties of the cell can be evaluated. In some cases, the microfluidic chip is made of PDMS attached to a cover glass and connected to at least two inlets (i.e., one for a first syringe with a cell suspension including biomolecules, and one for a second syringe with a measurement buffer) and at least one outlet connected by a narrow portion of the channel in which the detection is performed. To quantify the mechanical properties of the cells, the microfluidic chip is placed on an inverted microscope equipped with a high-speed CMOS camera and synchronized strobed LED bright field illumination.
[0091] A method for detecting biomolecules in a sample by mechanical characterization (e.g., by real-time deformability cytometry (RT-DC) measurement) comprises the following steps:
[0092] (i) treating mammalian cells with a sample or a control group;
[0093] (ii) preparing a cell preparation including cells (e.g., at 3-5×10 6 cells / mL final concentration);
[0094] (iii) preparing a microfluidic chip having a channel width suitable for cells (for example, the cell diameter can cover 20%-90% of the channel width, preferably 30%-90% of the channel width);
[0095] (iv) loading the cell preparation onto a microfluidic chip;
[0096] (v) measuring the mechanical properties of cells at an appropriate flow rate;
[0097] (vi) performing image processing to determine the mechanical properties of the cells (e.g., bright field images for cell size, deformation, area ratio, and aspect ratio);
[0098] (vii) comparing the detected mechanical properties of the sample cell preparation with reference values of a control cell preparation to infer the presence or absence of the biomolecule.
[0099] In step (ii) of the method for detecting biomolecules in a sample by mechanical characterization by RT-DC measurement, the measurement buffer (MB) can be viscosity-adjusted (e.g., adjusted to a final viscosity of 25 mPa s at 23-25°C for blood and bone marrow measurements; as described in Table 3 of HerBig et al. doi:10.1007 / 978-1-4939-7346-0_15), osmolarity-adjusted (e.g., for standard cell lines or primary cells from humans or mice, an MB osmolarity of 320±20 mOsm / kg is sufficient) and pH-controlled (e.g., pH 7.4). Due to the rapid sedimentation, only blood cells and bone marrow cells need to be measured at concentrations above 0.5%. Otherwise, any concentration between 0.4-1% can be used. For example, 0.6% (w / v) methylcellulose is dissolved in PBS, mixed thoroughly and filtered. It should be noted that other buffers, such as serum or cell culture media, can also be used. Since RT-DCs are prepared for cells in suspension, adherent cells need to be detached using, for example, trypsin.
[0100] In step (v) of the method for detecting biomolecules in a sample by mechanical characterization by RT-DC measurement, the flow rate can be adjusted according to the microfluidic chip size (channel width) and the viscosity of the measurement buffer (MB). In some cases, the channel width is between 10 μm and 40 μm, and the cell size is between 2 μm and 40 μm (cell diameter), or between 5 μm and 1050 μm. 2 For a channel width of 10 μm, the cell size is preferably between 3 μm and 9 μm (diameter) or between 7 μm 2 With 64μm 2 For a channel width of 10 μm and a MB viscosity of 15 mPa s, preferably the total flow is between 0.004 μL / s and 0.016 μL / s, the sample flow is between 0.001 μL / s and 0.004 μL / s, and the sheath flow is between 0.003 μL / s and 0.012 μL / s. For a channel width of 20 μm, the cell size is preferably between 6 μm and 18 μm (diameter) or between 28 μm. 2 With 254μm 2For a channel width of 20 μm and a MB viscosity of 15 mPa s, preferably the total flow rate is between 0.004 μL / s and 0.12 μL / s, the sample flow rate is between 0.01 μL / s and 0.004 μL / s, and the sheath flow rate is between 0.03 μL / s and 0.12 μL / s. For a channel width of 30 μm, the cell size is preferably between 9 μm and 27 μm (diameter) or between 28 μm. 2 With 254μm 2 (area). For a channel width of 30 μm and a MB viscosity of 15 mPa s, the preferred total flow rate is between 0.16 μL / s and 0.32 μL / s, the sample flow rate is between 0.04 μL / s and 0.08 μL / s, and the sheath flow rate is between 0.12 μL / s and 0.24 μL / s. For a channel width of 15 μm and a MB viscosity of 25 mPa.s, the preferred total flow rate is between 0.008 μL / s and 0.024 μL / s, the sample flow rate is between 0.002 μL / s and 0.006 μL / s, and the sheath flow rate is between 0.006 μL / s and 0.018 μL / s. For a channel width of 20 μm and a MB viscosity of 25 mPa.s, the preferred total flow rate is between 0.02 μL / s and 0.06 μL / s, the sample flow rate is between 0.005 μL / s and 0.015 μL / s, and the sheath flow rate is between 0.015 μL / s and 0.045 μL / s. For a channel width of 30 μm and a MB viscosity of 25 mPa.s, the preferred total flow rate is between 0.08 μL / s and 0.16 μL / s, the sample flow rate is between 0.02 μL / s and 0.04 μL / s, and the sheath flow rate is between 0.06 μL / s and 0.12 μL / s. For a channel width of 40 μm and a MB viscosity of 25 mPa.s, the preferred total flow is 0.16 to 0.3 μL / s, the sample flow is 0.04 to 0.075 μL / s, and the sheath flow is 0.12 to 0.225 μL / s. For a channel width of 40 μm, the preferred cell size is between 12 μm and 36 μm (diameter) or between 113 μm 2 1018μm 2 For a channel width of 40 μm and a MB viscosity of 15 mPa s, preferably the total flow is between 0.32 μL / s and 0.96 μL / s, the sample flow is between 0.08 μL / s and 0.24 μL / s, and the sheath flow is between 0.24 μL / s and 0.72 μL / s.
[0101] In step (vi) of the method for detecting biological molecules in a sample by mechanical characterization through RT-DC measurement, image processing may include one or more of the following steps, which do not necessarily occur in the following order: (vi-i) background subtraction; (vi-ii) threshold filtering; (vi-iii) contour finding; (vi-iv) object segmentation, which can be based on pixel classification; and (vi-v) contour processing, which is used to estimate cell size, position, deformation, brightness, etc.
[0102] For mechanical characterization, the size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties (such as Raman and / or Brillouin scattering), dielectric and acoustic impedance, elasticity (elastic modulus, Young's modulus), stiffness, deformability, and / or viscosity of the cells can be characterized.
[0103] Parameters Cell size can be measured as diameter in μm (cell diameter) and / or in μm 2 The projected cell cross-sectional area (cell area) is measured in units.
[0104] The parameter deformation d is based on a feature called circularity c and is defined as:
[0105] where A is the area enclosed by the contour (i.e., the projected cross-sectional area of the cell is obtained from the number of pixels within the cell boundary defined by the contour), and P is the perimeter of the contour, e.g., as described in Urbanska et al. doi:10.1016 / bs.mcb.2018.06.009.
[0106] The parameter area ratio is defined as:
[0107]
[0108] Among them, A c is the area of the convex hull of the detected contour, and A R is the area of the initially detected contour, for example, as in Urbanska et al. doi:10.1016 / bs.mcb.2018.06.009 Figure 4 For determining cell mechanical parameters, such as deformation or derived Young's modulus, the area ratio is preferably set between 1.00 and 1.10, more preferably between 1.00 and 1.05.
[0109] The parameter aspect ratio is defined as the ratio between the width and the height of the cell outline bounding box (x-dimension / y-dimension).
[0110] In step (vii) of the method for detecting a biomolecule in a sample by mechanical characterization by RT-DC measurement, the mechanical properties of the sample cell preparation are compared with the mechanical properties of a control cell preparation (reference value) to infer the presence of the biomolecule. In some cases, a statistical model can be applied to evaluate the changes between the sample cell preparation and the control cell preparation observed by RT-DC measurement (reference value). It is not important if the exact amount or change in amount determined by standard techniques is statistically significant.
[0111] Changes in deformation of cells exposed to a sample compared to cells exposed to a control (reference) value can indicate the presence of specific biomolecules in the sample. For example, a scatter plot of deformation measured from RT-DC versus cell size (area) can be used to compare mechanical properties.
[0112] In one aspect, the concentration of the detected biomolecule can be assessed. This can be achieved by correlating the value of one or more quantifiable physical parameters with a specific concentration of the biomolecule to be detected. For example, the method can include a calibration step in which different biomolecule concentrations are correlated with one or more physical parameters of the cell.
[0113] Simultaneous detection of two or more different biomolecules
[0114] One aspect of the invention includes a method for simultaneously detecting at least two types of biomolecules (e.g., antibodies with different antigenicity) in a sample. This includes adding a sample including at least two different biomolecules to a cell population including at least two cell subpopulations. The first cell subpopulation is arranged so that the first biomolecule to be detected can interact with the cells (feature (i)), and the first cell subpopulation is characterized by fluorescence behavior (feature (ii)). The second cell subpopulation is arranged so that the second biomolecule to be detected can interact with the cells (feature (i)), and the second cell subpopulation is characterized by different fluorescence behavior compared to the first cell subpopulation (feature (ii)). Therefore, in the cell population, at least two cell subpopulations differ in features (i) and (ii). For example, these two features can be detected simultaneously in a microfluidic channel.
[0115] For example, to detect three different biomolecules A, B, and C in a sample, a cell population including three cell subpopulations A, B, and C can be used. Cell subpopulation A expresses (i) a receptor A specific for biomolecule A and (ii) a fluorescent molecule A specific for cell subpopulation A. Cell subpopulation B expresses (i) a receptor B specific for biomolecule B and (ii) a fluorescent molecule B specific for cell subpopulation B. Cell C expresses (i) a receptor C specific for biomolecule C and (ii) a fluorescent molecule C specific for cell subpopulation C. When the changes in the physical properties of the cells (e.g., mass density, size, or mechanical properties) and the fluorescence behavior of the cell subpopulations A, B, and C are read in combination, the presence of biomolecules A, B, and / or C in the sample can be inferred compared to a reference value.
[0116] A method for detecting at least two different biomolecules in a sample by simultaneously performing mechanical characterization and fluorescence characterization similar to flow cytometry (e.g., by real-time fluorescence and deformability cytometry (RT-FDC) measurement) comprises the following steps:
[0117] (i) preparing a cell population (e.g., mammalian cells) comprising at least two cell subpopulations: wherein a first cell subpopulation is configured such that a first biomolecule to be detected can interact with cells of the first cell subpopulation, and the first cell subpopulation is characterized by fluorescence behavior; and wherein a second cell subpopulation is configured such that a second biomolecule to be detected can interact with cells of the second cell subpopulation, and the second cell subpopulation is characterized by different fluorescence behavior than the first cell subpopulation;
[0118] (ii) treating a cell population with a sample or a control group, wherein cells in the cell population are configured so that the biomolecule to be detected can interact with the cells, thereby changing one or more properties of the cells;
[0119] (iii) preparing a cell population preparation comprising cells in a measurement buffer (MB) of methylcellulose contained in a physiological buffer;
[0120] (iv) preparing a microfluidic chip having a channel width suitable for analyzing a single cell of a cell population (e.g., the cell diameter can cover 20%-90% of the channel width);
[0121] (v) loading the cell population preparation into a microfluidic chip;
[0122] (vi) simultaneously measuring cell morphology, cell mechanics (e.g., by brightfield imaging), and cell fluorescence (e.g., by multicolor imaging) of individual cells in a cell population at appropriate flow rates;
[0123] (vii) assigning the single cell to the first cell subpopulation or the second cell subpopulation based on its fluorescence behavior;
[0124] (viii) comparing the detected mechanical property of the first cell population with a reference value to infer the presence or absence of the first biomolecule to be detected; and
[0125] (ix) comparing the detected mechanical property of the second cell preparation with a reference value to infer the presence or absence of a second biomolecule to be detected.
[0126] In step (vi) of the method for detecting at least two biomolecules in a sample by simultaneous mechanical characterization and flow cytometry-like fluorescence characterization, measuring fluorescence allows two or more cell subpopulations to be distinguished by their unique fluorescence behavior to cell subpopulations (and receptors for specific biomolecules expressed in the subpopulations). The cell surface can be labeled with a fluorescent molecule, or the cell can express a heterologous fluorescent molecule (e.g., a fluorescent chemical compound, a fluorophore, or a fluorochrome). When each subpopulation expressing a fluorescent molecule with different spectral properties is mixed in a cell population, individual cells can be assigned to their subpopulations by multicolor imaging (e.g., by using multichannel scanning). In order to allow spectral distinction between cell subpopulations, suitable fluorophores and emission filters can be selected to minimize the spectral overlap between the emission profiles of the two fluorophores, thereby distinguishing the spectra. Preferably, the emission profiles of the fluorophores are at least 30 nm apart. In order to distinguish two cell subpopulations, a dual-channel fluorescence experiment can be performed using two suitable dyes.
[0127] The present method can be further combined with standard methods (e.g., proteomics, transcriptomics, genomics, and metagenomics). For example, for clinical diagnosis, methods such as enzyme-linked immunosorbent assay (ELISA), quantitative real-time PCR (RT-qPCR), next generation sequencing (NGS) analysis, rapid testing, point of care (POC) testing, liquid chromatography, and / or mass spectrometry can be used.
[0128] Samples, biomolecules and cells used in this method
[0129] One aspect of the invention includes detecting one or more biomolecules in a sample, comprising adding cells to the sample.
[0130] The sample can be a fluid, preferably a liquid. The sample can be obtained from a subject, such as saliva, blood, serum, excreta (e.g., urine, feces), semen, sweat, tears, body fluids (e.g., cerebrospinal fluid, CSF) and body tissue of the subject. In some cases, the sample can be processed before the step of combining the sample with the cell (or cell group) in the present method, for example, by filtering, purifying and / or diluting.
[0131] The cells used in the present method can be mammalian cells, more preferably human, mouse, rat or hamster cells. For example, the cells can be myeloid leukemia cell lines (K562, HL60), breast cancer cell lines (MDA-MB-231) or other cancer cell lines (e.g., H1975, HCC827, TMet, TnonMet and TMet-Nkx2-1, L1210), etc. The samples and cells can be of natural origin (e.g., biological species) or synthetic origin (e.g., samples of non-natural origin). In some cases, the samples and cells are from the same biological species (e.g., both are from humans), or from different biological species (e.g., samples from human and mouse cells).
[0132] When the cells are added to the sample, the cells are configured so that the biomolecule to be detected can interact with the cells, thereby changing one or more properties of the cells. In some cases, the interaction between the biomolecules in the sample and the cells is mediated by receptors. The receptors can be specific for a class of biomolecules (e.g., proteins), a series of biomolecules (e.g., antibodies), or a single biomolecule (e.g., an autoantibody with a specific glycosylation pattern). Mammalian cells can express natural receptors (such as cell surface molecules) including their natural conformations and post-translational modifications (e.g., phosphorylation, ubiquitination, glycosylation, palmitoylation). For example, a natural receptor can be a signaling receptor that regulates the physiological response of the cell, such as a G protein-coupled receptor (GPCR). Synthetic receptors can be derived from natural receptors, for example, by designing residues to increase their affinity or specificity for a target biomolecule. Cells can be modified to express synthetic receptors, for example, by genome editing.
[0133] In some cases, the biomolecule is an antibody that interacts with a cell receptor, preferably a cell surface receptor. In some cases, the antibody is an autoantibody. In some cases, the method for detecting specific autoantibodies is performed by using mammalian cells expressing natural or recombinant receptors of specific autoantibodies. In some cases, in order to detect autoantibodies, cells expressing G protein coupled receptors (GPCRs) such as β2-adrenoceptor (β2-adrenoceptor, β2-fAAB), α1-adrenoceptor (α1-adrenoceptor, α1-fAAB), angiotensin II AT1 receptor (angiotensin II AT1-receptor, AT1-fAAB) and nociception-like opioid receptor (nociception-likeopioid receptor, NOC-fAAB), muscarinic m 2 Receptor (muscarinic M2-receptor, m 2 -fAAB), MAS-receptor (MAS-fAAB) and ETA-receptor (ETA-fAAB).
[0134] One aspect of the invention includes a cell that is configured to change at least one of its properties when exposed to a biomolecule, wherein at least one of the properties of the cell can be measured by a physical phenotype, and wherein the cell is arranged to maintain a different property when exposed to the biomolecule, the different property being specific to the modified cell. In some cases, the physical phenotype is completed in less than 0.001 seconds. In some cases, the property that is maintained (i.e., unchanged or statistically not significantly changed between a sample and a control group) is the fluorescent behavior of the cell. In some cases, the cell has a smooth outline and cell size (in μm) between 25 μm and 225 μm, preferably between 100 μm and 175 μm. 2 However, contours are not necessarily smooth, and it may not even be necessary to detect contours to calculate cell size.
[0135] Medical applications of the method
[0136] One aspect of the invention includes detecting biomolecules in samples for diagnostic applications. Samples can be collected from the same or different bodily fluids of a subject over a period of time (e.g., several times a day, every day for several weeks, or at specified time intervals for longer periods of time, such as months or years) to monitor the presence or concentration of specific biomolecules and / or changes in biomolecule composition (e.g., an increase in biomolecule A accompanied by a decrease in biomolecule B).
[0137] In some cases, biomolecules are detected in samples to monitor the disease progression or response to treatment of the subject. In some cases, the sample is collected before and after the treatment (e.g., medical treatment) of the subject. In the case where it has been previously determined that the subject suffers from a disease or disorder, the method can be used to identify a therapy suitable for the disease or disorder, such as by detecting a change in at least one property of the cell after administering a drug treatment of an amount and duration sufficient to treat the disease or disorder. For example, the method comprises the following steps: obtaining a sample from a subject's body fluid (e.g., saliva, blood, urine, or cerebrospinal fluid), preparing the obtained sample for analysis, combining the sample with a cell; detecting at least one property of the cell, and inferring the presence, absence, or concentration of the biomolecule in the sample.
[0138] In some cases, subjects who test negative for the disease or subjects before the disease can be used as control samples to infer reference values for the step of comparing the detected properties of the cells with reference values to infer the presence or absence of biomolecules. In some cases, if it is known that there are gender differences in the response to the disease, the control group can be adjusted accordingly. In some cases, subjects who test negative for COVID-19 disease (e.g., by RT-qPCR detection of nasopharyngeal swab samples) can be used as a control group for detecting biomolecules (such as autoantibodies) in samples from patients with long-term COVID-19 (Long-COVID-19, PASC).
[0139] Compared to healthy control subjects, subjects with autoimmune diseases show abundant autoantibody levels, including autoimmune diseases such as systemic lupus erythematosus (e.g., anti-interferon-α (IFN-α) autoantibodies); idiopathic inflammatory myopathies such as sporadic inclusion body myositis (e.g., anti-cytoplasmic 5′-nucleosidase 1A (anti-cN1A) autoantibodies); encephalitis; rheumatoid arthritis (e.g., anti-ADAM33, anti-Honerin, anti-HCN3 autoantibodies); multiple sclerosis (e.g., anti-Kir4. 1 autoantibodies); interstitial lung disease (e.g., anti-BPIFB1 autoantibodies); type I diabetes (e.g., anti-Znt8, anti-GAD65, anti-IA2 autoantibodies); scleroderma (e.g., anti-RPC1 autoantibodies); systemic autoimmune diseases (e.g., anti-Ro52, anti-Ro60, anti-RNP-70 autoantibodies); disseminated nontuberculous mycobacterial infection (e.g., anti-interferon-γ (IFN-γ) autoantibodies); or, autoimmune thyroid disease, such as Graves' disease or Hashimoto's thyroiditis (e.g., anti-TSH receptor (TRAb) autoantibodies). Other factors (e.g., environmental factors or diseases) can also affect the subject's autoantibody levels.
[0140] In one aspect, systems and methods can be used to detect autoantibodies in body fluids obtained from subjects suspected of having a disease or disorder (e.g., animal disease models or patients) or subjects exposed to a specific treatment (e.g., studying the progress of therapeutic treatments, such as, after the response to a drug or an immunization vaccination). Systems for detecting autoantibodies can include microfluidic channels, cells expressing receptors for autoantibodies, and detectors of cell properties that change when receptors interact with autoantibodies. After sample preparation, cells are combined with samples before or during their passage through microfluidic channels. Subsequently, the properties of the cells are measured and compared with the properties of the control group measurements and / or control group values (reference values). If one or more properties of the cells are changed compared to the reference values, the presence of autoantibodies is detected.
[0141] For diagnostic applications as well as therapeutic and treatment methods, the biomolecule can be a marker for a disease or disorder. For example, patients with long-term COVID-19 have increased levels of autoantibodies (e.g., anti-GPCR autoantibodies; see [7] Wallukat et al., doi:10.1016 / j.jtauto.2021.100100). Detection of such anti-GPCR autoantibodies is also included in the present method.
[0142] The kit or cells may be used in a method for detecting a biomolecule in a sample obtained from a patient, preferably wherein the sample is saliva, blood, urine or cerebrospinal fluid (CSF).
[0143] Experimental Section
[0144] The following are examples of the systems and methods disclosed herein.It will be appreciated that various other aspects may be practiced given the general and detailed descriptions provided elsewhere herein.
[0145] Detection of biomolecules by measuring changes in cell deformability ( Figure 4 )
[0146] For biomolecule detection in a sample, the presence or absence of a biomolecule of interest (e.g., an autoantibody) can be detected by mechanically phenotyping mammalian cells with a sample that includes the biomolecule of interest (e.g., an autoantibody). High-throughput mechanical phenotyping can be performed by real-time deformable cytometry (RT-DC), which allows for instant analysis of deformable cell shape.
[0147] Samples. Sample 1, vehicle for reference values: water. Sample 2, beta 2 agonist. Sample 3, human serum including autoantibodies targeting G protein coupled receptors (GPCRs) such as beta 2-adrenergic receptor: blood samples collected from long-term COVID-19 patients after recovery from acute illness. Patient serum was isolated.
[0148] Cells. Experiments were performed on HL60 cells, a myeloid precursor cell line that served as a standard suspension cell line in comparative experiments with optical expanders. Where appropriate, results were confirmed with primary cells. The HL60 cell line was originally derived from a patient with APL in 1977 and modified to the HL60 / S4 line currently used in this work (a generous gift from D. and A. Olins, Department of Pharmacy, School of Pharmacy, University of New England, who had confirmed the cell line prior to sending it). Cells were cultured in RPMI-1640 medium with 10% FCS (Life Technologies) and 1% penicillin / streptomycin (Life Technologies) in a standard incubator (Hera Cell, Thermo Scientific) at 37°C, 5% CO2 and 95% air. Cells were lysed every 48 h and resuspended to 2×10 5 The concentration of cells / ml was 100 cells / ml. For experiments, cells were harvested approximately 36 h after division during the exponential growth phase. Cells were initially checked for mycoplasma contamination (Mycoplasma kit, Sigma-Aldrich) and regularly refreshed from frozen stocks.
[0149] Cell culture. After thawing, equilibrate cells in culture for several days using appropriate cell culture media and cell culture conditions. Split cells in T25 flasks and 6-well plates for RT-DC measurements and treatments. Each condition is measured three times (e.g., three wells in a 6-well plate). Approximately 24 hours before RT-DC measurements, adjust the cell number to 1.0 × 10 5 cells / mL, and the total volume was 2.5 mL / well.
[0150] Combine cells with samples (treatment). Human HL60 cells were incubated with a reference (sample 1) or a β2-adrenergic receptor agonist (sample 2 or 3). The number of cells was adjusted to a final concentration of 5×10 6cells / mL. Transfer cells from each well to an appropriate tube for treatment. For sample 1 (reference group): the same amount of vehicle (e.g., water) as used for the drug (e.g., β2 agonist). For sample 2 (drug, β2 agonist): add the appropriate working concentration to the cell suspension. For sample 3 (containing human serum against β2 receptors): add the sample to a final volume of approximately 10% v / v, for example, add 10 μL of sample to 100 μL of cell suspension. For all samples 1 to 3, treatment was performed at room temperature for 10 min. After treatment, cells were collected by centrifugation (e.g., 200 x g, 3 min).
[0151] Next, RT-DC measurements were performed to detect changes in cell deformability in samples 2 and 3 compared to sample 1 (reference group).
[0152] For the measurement, 0.6% MC-PBS measurement buffer (MB0) was used and filtered through a 0.22 μm filter before use. A microfluidic chip with a measurement channel size of 30×30 μm (channel width 30 μm) was used. For each sample / condition, a new chip was used. For each sample / condition, the cell pellet was resuspended in 0.6% MC-PBS measurement buffer (MB) by avoiding the introduction of bubbles, e.g., 50 μL of 0.6% MC-PBS.
[0153] Appropriate measurement conditions were selected for the RT-DC device. Measurements of the cell-MB suspension were performed at a total flow rate of 0.1200 μL / s (equilibrium flow for at least 2 min). As an internal control, reservoir measurements were performed (e.g., HerBig et al., doi:10.1007 / 978-1-4939-7346-0_15). Figure 4 C), and then the channel measurement is performed at the end of the measurement channel. Bright field images are captured by a high-speed camera with a CMOS sensor mounted on one port of the microscope. The camera triggers the LED light source (the appropriate LED shutter time is selected to minimize motion blur).
[0154] Detection of changes. Deformation cytometry plots (scatter plots of deformation versus cell size (area) derived from RT-DC measurements) of HL60 cells show the deformation of each cell event and its corresponding measured cell area (μm 2 ).
[0155] Results. Figure 4 As shown in the contour plot of (d), the deformability cytometry plots indicate that cells treated with GPCR agonists (drugs that activate GPCRs in sample 2, or patient serum including GPCR autoantibodies in sample 3) are less deformed compared to control cells.
[0156] Industrial Applicability
[0157] The present system and method are reliable and effectively handle biomolecule detection for monitoring, biochemical research, medical diagnosis, predicting treatment response, understanding disease pathogenesis and drug development. Therefore, the present system and method are applicable in industry.
[0158] Further applications and practical developments in industry can be derived from this description through the general knowledge of a person skilled in the art.
[0159] References
[0160] [1]E.Drucker and K.Krapfenbauer, "Pitfalls and limitations intranslation from biomarker discovery to clinical utility in predictive and personalized medicine," 2013, doi:10.1186 / 1878-5085-4-7.
[0161] [2] R. Mayeux, "Biomarkers: Potential Uses and Limitations," NeuroRx, vol.1, no.2, pp.182–188, 2004, doi:10.1602 / neurorx.1.2.182.
[0162] [3] SBNimse, M.D. Sonawane, K.-S. Song, and T. Kim, "Analyst CRITICALREVIEW Biomarker detection technologies and future directions," Cite thisAnal., vol.141, p.740, 2016, doi:10.1039 / c5an01790d.
[0163] [4] P.-H.Wu et al., "Acomparison of methods to assess cell mechanicalproperties," Nat.Methods, 2018, doi:10.1038 / s41592-018-0015-1.
[0164] [5]M.Urbanska et al.,“A comparison of microfluidic methods for high-throughput cell deformability measurements,”Nat.Methods,vol.17,no.6,pp.587–593,2020,doi:10.1038 / s41592-020-0818-8.
[0165] [6]Burbelo and O’Hanlon,“New Autoantibody Detection TechnologiesYield Novel Insights into Autoimmune Disease”,Curr Opin Rheumatol.2014,doi:10.1097 / BOR.0000000000000107
[0166] [7]Wallukat et al.,"Functional autoantibodies against G-proteincoupled receptors in patients with persistent Long-COVID-19symptoms”,Journalof Translational Autoimmunity 4,2021,doi:10.1016 / j.jtauto.2021.100100
[0167] [8]Morgenthaler et al.,“Application of a bioassay with CHO cells forthe routine detection of stimulating and blocking autoantibodies to the TSH-receptor”,Horm Metab Res,1998,doi:10.1055 / s-2007-978858
[0168] [9]Otto et al.,“Real-time deformability cytometry:on-the-fly cellmechanical phenotyping”.Nat.Methods,2015,doi:10.1038 / nmeth.3281)
[0169]
[10] Herbig et al.,“Real-Time Deformability Cytometry:Label-FreeFunctional Characterization of Cells”,Humana Press,2018(doi:10.1007 / 978-1-4939-7346-0_15)
[0170]
[11] Al-Aly et al.,Nature 2021,“High-dimensional characterization ofpost-acute sequelae of COVID-19”,doi:10.1038 / s41586-021-03553-9
[0171]
[12] WO 2015 / 024690 A1,“Apparatus and method for determining themechanical properties of cells”
[0172]
[13] Urbanska et al.,chapter 10,“High-throughput single-cellmechanical phenotyping with real-time deformability cytometry”,Methods inCell Biology,pages 175-198,Volume 147,ISSN 0091-679X,2018Elsevier Inc.(doi:10.1016 / bs.mcb.2018.06.009)
[0173]
[14] Wallukat et al.,Anti-β1-Adrenoceptor Autoantibodies withChronotropic Activity from the Serum of Patients with Dilated Cardiomyopathy:Mapping of Epitopes in the First and Second Extracellular Loops,J.Mol.CellCardiol.27,397-406.
Claims
1. A method for detecting biomolecules in a sample, the method comprising: include: - adding cells to the sample, said cells being arranged such that said biomolecules to be detected can interact with said cells, thereby changing one or more properties of said cells, - detecting said property of said cell, and - comparing said detected property with a reference value to infer the presence or absence of said biomolecule and / or the concentration of said biomolecule.
2. The method according to claim 1, in, Said detecting of said property of said cell is performed in a microfluidic channel, wherein said sample is guided through said microfluidic channel, wherein preferably said detected property comprises a mechanical property, and wherein said cell preferably deforms within said channel.
3. The method according to claim 1 or 2, in, The cell is configured such that the interaction of the biomolecule with the cell is binding of the biomolecule to a receptor of the cell.
4. The method according to any one of the preceding claims, in, The cell is configured such that more than one type of biomolecule is able to interact with the cell, and wherein different types of biomolecules result in different detectable changes in a property of the cell.
5. The method according to any one of the preceding claims, in, The properties include one or more of the size, shape, structure, morphology, transit time, mass density, elastic and inelastic light scattering properties, such as Raman and / or Brillouin scattering, dielectric and acoustic impedance and / or deformability, elasticity and viscosity of the cell.
6. The method according to any one of the preceding claims, in, The cell is a mammalian cell, and Optionally, the cells include or consist of natural cells, transfected cells and / or synthetic cells.
7. The method according to any one of the preceding claims, in, The cell is configured to change a property of the cell when exposed to the biomolecule, and wherein the biomolecule is an antibody that interacts with a receptor of the cell, preferably a cell surface molecule, optionally wherein the antibody is an autoantibody targeting G protein coupled receptors (GPCRs).
8. A method according to any preceding claim, further comprising using the detected property to infer the concentration of the biomolecule in the sample.
9. The method according to any one of the preceding claims, in, The sample is a fluid, preferably a liquid; Optionally, wherein The fluid is obtained from a subject, further optionally, wherein the fluid is saliva, blood, excreta and / or a body fluid, preferably, wherein the excreta is urine, and / or wherein the body fluid is cerebrospinal fluid (CSF); and Optionally, wherein the subject is a mammal.
10. A method for detecting at least two types of biomolecules in a sample, the method comprising: include: - adding a cell population to the sample; wherein the cell population comprises at least two cell subpopulations or at least two cell groups from different sources: The first cell subpopulation / group is arranged such that a first type of biomolecule to be detected can interact with cells of the first cell subpopulation / group and the first cell subpopulation / group is characterized by a fluorescent behavior, and the second cell subpopulation / group is arranged so that a second type of biomolecule to be detected can interact with cells of the second cell subpopulation / group, and the second cell subpopulation / group is characterized by a different fluorescence behavior compared to the first cell subpopulation / group; and wherein the cell is configured so that the biomolecule to be detected can interact with the cell, thereby changing one or more properties of the cell; - detecting properties of said cells and the fluorescence behavior of said cells; - comparing the detected property with a reference value to infer the presence or absence of the biomolecule; - comparing the fluorescence behavior of the cells to assign the detected change in the property to a first type of cell or a second type of cell; and - inferring the presence or absence of a first type of biomolecule, and the presence or absence of a second type of biomolecule.
11. The method according to claim 10, in, The type of biomolecule is a different biomolecule that interacts with the cell, Optionally, wherein said biomolecule binds to a different receptor of said cell.
12. The method according to claim 10 or 11, in, The biomolecules are antibodies and the types of biomolecules are antigenically distinct antibodies, Wherein, the first type of antibodies can interact with cells of the first cell subpopulation / group but cannot interact with cells of the second cell subpopulation / group, and the second type of antibodies can interact with cells of the second cell subpopulation / group but cannot interact with cells of the first cell subpopulation / group.
13. The method according to any one of claims 10 to 12, in, The detected property of the cell is a mechanical property, and wherein the mechanical property and the fluorescence behavior of the cell are detected in a microfluidic channel.
14. A kit, wherein the kit is configured to detect biomolecules. include: - one or more cells arranged such that the biomolecule to be detected can interact with the cells and thereby change one or more properties of the cells, - means for detecting one or more properties of said cells, said kit preferably being arranged for use in a method according to one of the preceding claims.
15. A kit for use in a method for detecting one or more biomolecules in a sample obtained from a subject, preferably in, The sample is saliva, blood, urine or cerebrospinal fluid (CSF).
